Phase II study of docetaxel and estramustine in metastatic androgen-independent prostate cancer

By Guimaraes T.   Bento M.J.   Pinho T.   Guedes d.C.R.   Pinto F.  

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 159-159

Elsevier

Access to resources Recommend Favorite

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer

By Vaishampayan U.   Fontana J.   Du W.   Hussain M.  

Urology, Vol. 60, Iss. 6, 2002-12 ,pp. : 1050-1054

Elsevier

Access to resources Recommend Favorite

Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer

By Benaim E.A.   Pace C.M.   Lam P.M.   Roehrborn C.G.  

Urology, Vol. 59, Iss. 1, 2002-01 ,pp. : 73-78

Elsevier

Access to resources Recommend Favorite

Acid phosphatase: defining a role in androgen-independent prostate cancer

By Steineck G.   Kelly W.K.   Mazumdar M.   Vlamis V.   Schwartz M.   Scher H.I.  

Urology, Vol. 47, Iss. 5, 1996-05 ,pp. : 719-726

Elsevier

Access to resources Recommend Favorite

Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma

By Ghossein R.A.   Rosai J.   Scher H.I.   Seiden M.   Zhang Z.-F.   Sun M.   Chang G.   Berlane K.   Krithivas K.   Kantoff P.W.  

Urology, Vol. 50, Iss. 1, 1997-07 ,pp. : 100-105

Elsevier

Access to resources Recommend Favorite